J
James B. Young
Researcher at Cleveland Clinic
Publications - 538
Citations - 46895
James B. Young is an academic researcher from Cleveland Clinic. The author has contributed to research in topics: Heart failure & Transplantation. The author has an hindex of 102, co-authored 517 publications receiving 43826 citations. Previous affiliations of James B. Young include Case Western Reserve University & Baylor University.
Papers
More filters
importance of Treating Seizures and Acidosis
Steinn Jonsson,James B. Young +1 more
TL;DR: It is believed that prompt treatment of the acidosis and control of the seizures were of prime importance in the successful management of this patient, and the patient made a quick recovery.
Journal ArticleDOI
Donor or recipient hepatitis B seropositivity is associated with allograft vasculopathy.
Showkat A. Haji,Robin K. Avery,Mohamad H. Yamani,E. Murat Tuzcu,Tim Crowe,Daniel J. Cook,Steven D. Mawhorter,Robert E. Hobbs,James B. Young,Nicholas G. Smedira,Randall C. Starling +10 more
TL;DR: Preliminary results suggest that HBV seropositivity in donor or recipient may be associated with an increased risk for cardiac allograft vasculopathy.
Journal ArticleDOI
Bridge to eligibility: LVAS support in patients with relative contraindications to transplantation
James B. Young,Joseph G. Rogers,Peer M. Portner,Philip E. Oyer,Brooks S. Edwards,S.F Davis,T.B. Icenogle,F.L. Johnson,Robert L. Kormos,Steven L. Lansman,Susan Restaino +10 more
Journal ArticleDOI
Hyporesponsiveness to Darbepoetin Alfa in Patients With Heart Failure and Anemia in the RED-HF Study (Reduction of Events by Darbepoetin Alfa in Heart Failure) Clinical and Prognostic Associations
Peter van der Meer,Niels Grote Beverborg,Marc A. Pfeffer,Kurt Olson,Inder S. Anand,B. Daan Westenbrink,John J.V. McMurray,Karl Swedberg,James B. Young,Scott D. Solomon,Dirk J. van Veldhuisen +10 more
TL;DR: A poor response to darbepoetin alfa was associated with worse outcomes in heart failure patients with anemia, and patients with a poor response were difficult to identify using clinical and biochemical biomarkers.
Journal ArticleDOI
Heart failure, ventricular remodelling and the renin-angiotensin system: insights from recently completed clinical trials
TL;DR: Clinical drug trials in patients with heart failure indicate that vasodilators and, in particular, angiotensin-converting enzyme inhibitors, decrease heart failure mortality.